На главную
Результаты поиска “Clinical trials for lung cancer treatments”
New Cancer Treatment Is Incredibly Effective
 
09:21
Researchers from Stanford University looked into a possible cancer vaccine and through their clinical trials found out it is incredibly effective. Ana Kasparian, Grace Baldridge, and Mark Thompson, hosts of The Young Turks, discuss. Tell us what you think in the comment section below. http://www.tytnetwork.com/join Read more here: https://www.livescience.com/62161-cancer-vaccine-trial.html "A promising new cancer "vaccine" that cured up to 97 percent of tumors in mice will soon be tested in humans for the first time — but experts say that we're still a long way off from this type of drug being prescribed to cancer patients. Researchers from Stanford University will test the therapy in about 35 people with lymphoma by the end of the year, according to SFGate, a local news outlet in San Francisco. The treatment stimulates the body's immune system to attack cancer cells. In studies in mice with various cancers — including lymphoma, breast cancer and colon cancer — the treatment eliminated cancer tumors in 87 out of 90 mice, even when the tumors had spread to other parts of the body, the researchers said." Hosts: Ana Kasparian, Grace Baldridge, and Mark Thompson Cast: Ana Kasparian, Grace Baldridge, and Mark Thompson *** The Largest Online News Show in the World. Hosted by Cenk Uygur and Ana Kasparian. LIVE STREAMING weekdays 6-8pm ET. https://goo.gl/tJpj1m Subscribe to The Young Turks on YouTube: https://goo.gl/a3JY9i Like The Young Turks on Facebook: https://goo.gl/txrhrh Follow The Young Turks on Twitter: https://goo.gl/w6ahdV Buy TYT Merch: https://goo.gl/KVysaM Download audio and video of the full two hour show on-demand + the members-only post game show by becoming a member at https://goo.gl/v8E64M. Your membership supports the day to day operations and is vital for our continued success and growth. Young Turk (n), 1. Young progressive or insurgent member of an institution, movement, or political party. 2. A young person who rebels against authority or societal expectations.(American Heritage Dictionary)
Просмотров: 146549 The Young Turks
New Options for Lung Cancer Therapies
 
01:00:09
Dr. Joel Neal, a Stanford Cancer Institute researcher and oncologist, discussed clinical research on lung cancer therapies with a focus on immunotherapy and other targeted approaches.
Просмотров: 4782 Stanford Health Care
Clinical Trial Immunotherapy for Lung Cancer Treatment
 
02:27
New advances in treatment are helping more people, like Natalie Kelly, survive lung cancer. After chemotherapy did not work, she turned to a clinical trial for immunotherapy. Learn more from Dr. Suman Rao as she discusses immunotherapy for lung cancer treatment. To learn more about lung cancer treatment visit http://bit.ly/2iXiO2z.
Просмотров: 269 MedStar Health
Lung Cancer Clinical Trial for NSCLC
 
07:16
A new and innovative lung cancer clinical trial is being conducted at UCLA. This trial tests the use of an aromatase inhibitor in conjunction with the standard lung cancer chemotherapy to find better treatments and hopefully cures for lung cancer. This trial is based upon the concept that estrogen serves as the basic fuel for lung cancer. The trial is for advanced non-small cell lung cancer (NSCLC).
Просмотров: 311 Demand Cures
Immunotherapy Advances in Small Cell Lung Cancer
 
27:08
Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. https://www.cancerresearch.org/webinars On August 17, 2018, the FDA approved the first immunotherapy—the checkpoint inhibitor nivolumab (Opdivo®, Bristol-Myers Squibb)—for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typically comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer. Matthew Hellman MSKDr. Matthew Hellmann specializes in the care of patients with lung cancers. He is dedicated to identifying better treatments for people with all stages of disease and to providing compassionate care for patients and their families. His research focuses on developing innovative and effective ways to harness the body’s immune system to fight cancer. He is a member of the Immunotherapeutics Group, which designs and leads early-phase clinical trials of immunotherapies for patients with a variety of different cancers. The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is hosted by our science writer, Arthur Brodsky, Ph.D. This special episode in our webinar series is made possible with generous support from Bristol-Myers Squibb. Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series. https://www.cancerresearch.org/webinars
Просмотров: 10143 Cancer Research Institute
Overcoming Terminal Lung Cancer with Clinical Trial - Lehigh Valley Health Network
 
04:21
When war veteran Jonathan Gyuran experienced chest pains at work, he thought he was having a heart attack. Within 24 hours, tests conducted at Lehigh Valley Health Network revealed the true cause: cancer that had spread to both lungs. Lehigh Valley Health Network medical oncologist Brian Patson, MD, suggested a clinical trial that was ultimately able to help Jonathan beat the odds and put his cancer into remission. Lehigh Valley Health Network Cancer Institute is proud to be part of the Memorial Sloan Kettering Cancer Alliance, an initiative to improve the quality of care and outcomes for patients with cancer in community health settings. Learn more about our clinical trials and partnership with the Memorial Sloan Kettering Cancer Alliance at LVHN.org/msk.
Просмотров: 2766 Lehigh Valley Health Network
Keeping Lung Cancer Under Control: Bob's Immunotherapy Story
 
04:05
When Bob was diagnosed with non-small cell lung cancer (NSCLC), his wife Julia was so devastated that she cried for several months thinking about her life without him. Bob weighed all his options with his oncologist. After trying chemotherapy, Bob found another treatment that would give him hope—immunotherapy. He enrolled in a clinical trial of a treatment that helps T-cells to recognize and attack cancer cells. Six years later, Bob's health is stable and he remains optimistic. Bob and Julia urge others to not give up hope because advances in cancer research are rapidly providing new treatment options. Help us continue to bring hope to patients with cancer and support lifesaving (and extending) cancer research: http://bit.ly/MatchCRI
Просмотров: 1765 Cancer Research Institute
Navigating Clinical Trials and Treatments for Lung Cancer
 
17:32
Lung Cancer Alliance clinical research coordinator Andrew Ciupek speaks about recent progress in lung cancer advocacy and enrolling in clinical trials. Learn more about NYU Langone’s Perlmutter Cancer Center: http://nyulangone.org/locations/perlmutter-cancer-center
Просмотров: 28 NYU Langone Health
Lung Cancer and a Clinical Trial | Abi's Story
 
03:51
Abi had stage 4 lung cancer. She turned to Penn's Abramson Cancer Center for treatment, and we connected her with a clinical trial for lung cancer. Eight years, and four grandkids later, Abi radiates hope. #CureIsWithin
Просмотров: 2091 Penn Medicine
Living Healthy:  Clinical Trials for Lung cancer
 
04:03
Living Healthy: Clinical Trials for Lung cancer
Просмотров: 53 KHON2 News
The Latest in Lung Cancer Treatment
 
02:50
From radiation to immunotherapy to clinical trials, learn more about the most current lung cancer treatments from the experts at Levine Cancer Institute.
Просмотров: 719 Atrium Health
Understanding Cancer Clinical Trials
 
17:10
Understanding Cancer Clinical Trials - National Institutes of Health 2007 - Publication Q021 - National Cancer Institute. Used as a tool for health care professionals when discussing clinical trials with possible participants and their families. Discusses types of clinical trials, how they are conducted, and factors to think about.
Просмотров: 2427 PublicResourceOrg
Lung Cancer Clinical Trials: Advances in Immunotherapy
 
29:41
NCI’s Dr. Shakun Malik, head of thoracic oncology therapeutics, and Janet Freeman-Daily, lung cancer patient activist and founding member of #LCSM, host a 30-minute Facebook Live event. The event streamed on November 17 at 8:00 pm ET on http://www.Facebook.com/cancer.gov. For more information on lung cancer, go to http://www.cancer.gov/lung
Просмотров: 737 National Cancer Institute
Clinical trial was the right choice for lung cancer survivor
 
02:15
When Georgia Dominick was diagnosed with stage IV metastatic lung cancer in Aug. 2014, an Alabama oncologist told her she only had a year left to live. But Georgia didn’t accept that prognosis and came to MD Anderson instead. Here, she took part in a clinical trial involving a new immunotherapy drug for people with her exact type of cancer. She is now two years post-diagnosis, and is considered in remission. “If I had the choice of going anywhere else in the world for free, I would stay right here,” she says. MD Anderson offers many clinical trials for all different cancers. To learn more about clinical trials and search for clinical trials, visit https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials.html
Просмотров: 1045 MD Anderson Cancer Center
FDA pulls Keytruda from two clinical trials after deaths
 
00:46
Although the FDA approved Keytruda in 2016 to help treat lung cancer, as an "alternative to chemotherapy," they recently put two trials on hold that involved the drug. UPI says that deaths were reported after two clinical trials mixed Keytruda with two other therapies. The trials reportedly investigated whether Keytruda could help people combat multiple myeloma. This use had not previously been approved by the FDA. An FDA spokesperson said that while trials are evaluated for risks, their purpose is to provide further insight into the safety of treatments. They added, "When significant safety issues do arise, we must work quickly to prevent further injury or deaths." https://www.upi.com/Health_News/2017/09/01/FDA-pulls-Keytruda-from-two-clinical-trials-after-deaths/7941504269174/ http://www.wochit.com This video was produced by YT Wochit News using http://wochit.com
Просмотров: 1065 Wochit News
This Cuban lung cancer drug is giving some U.S. patients hope
 
06:49
A promising lung cancer treatment from Cuba is getting attention from U.S. patients, some of whom are already traveling there to try the drug in hopes of stopping their cancer from growing. American doctors can't prescribe CIMAvax because the Food and Drug Administration won’t approve it until U.S. clinical trials can prove its effectiveness. Special correspondent Amy Guttman reports.
Просмотров: 11825 PBS NewsHour
Surviving With Metastatic Lung Cancer Thanks to Research
 
05:07
November is Lung Cancer Awareness Month. Learn how cancer targeted therapy and clinical trials are helping Ginger live well with stage 4 lung cancer: http://the.aacr.org/kr3E
Просмотров: 19514 American Association for Cancer Research
New Treatment for Early Stage Lung Cancer
 
04:20
Learn more about this clinical trial http://clinicaltrials.gov/ct2/show/NCT00840749 Patients who cannot have surgery for an early stage lung cancer may now benefit from a new radiation therapy technology called stereotactic radiation therapy (STARS). This treatment can typically be given in 3 or 4 days as opposed to the 5 or 6 weeks with conventional radiation therapy. For patients who CAN have surgery, an operation that removes the lobe of the lung containing the cancer and lymph nodes is the current standard of care. Because of the good results seen so far with stereotactic radiation therapy, it is now being considered as an alternative to surgery for patient who are fit enough to have surgery. Jack Roth, M.D., in the thoracic surgery department at MD Anderson Cancer Center, discusses this clinical trial (STARS) that compares stereotactic radiation therapy with traditional surgery.
Просмотров: 9052 MD Anderson Cancer Center
For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds
 
05:52
For many lung cancer patients, Keytruda is a better initial treatment than chemotherapy, study finds lung cancer, immunotherapy, chemotherapy, cancer treatment, clinical trials, medical research, ASCO, American Society of Clinical Oncology https://www.youtube.com/channel/UCd4_4MPV20qVj80Rm_cQHOw?sub_confirmation=1 In findings that may allow many lung cancer patients to avoid chemotherapy, a large clinical trial has shown that the immunotherapy drug Keytruda is a more effective initial treatment for two-thirds of patients with the most common type of lung cancer. Compared with advanced small-cell lung cancer patients who got chemotherapy, those treated first with Keytruda had a median survival time that was four to eight months longer. Advertisement The difference was greatest among patients whose cancers harbored high levels of the genetic mutations Keytruda uses to target malignancy. But even patients whose cancers had very low levels of these mutations outlived patients who got chemotherapy by a median of four months. In addition, treating lung cancer patients with Keytruda improved quality of life. Among those who got the immunotherapy drug, only 18% experienced severe side effects, compared with 41% on chemotherapy. The findings, presented this week at the annual meeting of the American Society of Clinical Oncology, will probably expand Keytruda’s use as a first-line treatment for advanced small-cell lung cancer, the most common form of the disease. At the same time, it’s sure to raise dilemmas for physicians and insurers struggling to identify when and in which advanced lung cancer patients the use of a very costly new medication makes sense. A year’s therapy with Keytruda can cost as much as $150,000. The cost of the chemotherapy cocktails to which it was compared in the new study is a few thousand dollars. In 2016, the Food and Drug Administration approved the marketing of Keytruda (also known as pembrolizumab) for use in lung cancer patients whose cancers had been genetically tested and were found to have levels of PD-L1 — a mutation that Keytruda targets — of 50% or higher. About one-third of patients with advanced non-small cell lung cancer meet this criterion. The new clinical trial, called Keynote-042, tested Keytruda’s effectiveness in newly diagnosed patients whose PD-L1 levels were as low as 1% — a population that represents two-thirds of those with small cell lung cancer. Researchers randomly assigned 1,274 people with advanced disease to receive one of two kinds of chemotherapy — either paclitaxel (marketed as Taxol) plus carboplatin or pemetrexed (marketed as Alimta) plus carboplatin — or Keytruda. Then, researchers followed their cases for a median of 12.8 months. Among patients whose PD-L1 levels were from 1% to 19%, those who got Keytruda lived for a median of 16.7 months after diagnoses while those who got chemotherapy lived a median of 12.8 months. Among patients with PD-L1 levels from 20% to 49%, those who got Keytruda lived a median of 17.7 months compared with 13 months for patients on chemotherapy. Patients whose PD-L1 levels were above 50% — those for whom Keytruda already has the FDA’s blessing — survived a median of 20 months with Keytruda, compared with 12.2 months for chemotherapy. The study has not yet
Просмотров: 235 Dongo NEWS
Central Texas Lung Cancer Patient Finds Success in Clinical Trial Treatment
 
02:31
Carol Houston visits Waco’s Texas Oncology every two weeks for treatment. Since February 2015, she’s participated in clinical trials for Opdivo after it was recommended by her physician, Dr. Thomas Harris.
Просмотров: 267 TexasOncology
Lung Cancer: New Therapies and Clinical Trials | City of Hope's Karen Reckamp, M.D.
 
02:31
Karen Reckamp, M.D., co-director of the Lung Cancer and Thoracic Oncology Program, discusses her focus on clinical trials and new treatments for lung cancer. For more information on City of Hope's lung cancer program, please go to: http://www.cityofhope.org/lung-cancer ############################ City of Hope is a leading research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope's main hospital is located in Duarte, Calif., just northeast of Los Angeles, with community clinics in southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S.News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics. For more information, visit www.cityofhope.org. ############################ CONNECT WITH CITY OF HOPE http://www.facebook.com/cityofhope http://www.twitter.com/cityofhope http://breakthroughs.cityofhope.org http://thehelix.cityofhope.org http://www.pinterest.com/cityofhopepins http://www.flickr.com/cityofhope http://www.causes.com/cityofhope and more at http://www.cityofhope.org/getsocial
Просмотров: 1203 City of Hope
Lung cancer survivor: Advice for cancer patients considering a clinical trial
 
01:16
After a CT scan revealed a 5 cm mass on his lung, lung cancer patient Tom Barber underwent a video-assisted thoracotomy at The University of Texas MD Anderson Cancer Center in August 2009. He subsequently considered chemotherapy and a clinical trial for follow-up lung cancer treatment. Ultimately, Barber chose to participate in a clinical trial. Although he experienced many side effects as a result of the clinical trial, he encourages other cancer patients to participate in a clinical trial, if there's one that's appropriate for their particular cancer diagnosis. Today, Barber is lung cancer-free. Read Barber's story: http://www.cancermoonshots.org/stories-hope/tom-barber Learn about MD Anderson's Lung Cancer Moon Shot: http://www.cancermoonshots.org/moon-shots/lung
Просмотров: 856 MD Anderson Cancer Center
Dr. Daly on Clinical Trials With Radiation Therapy in Lung Cancer
 
01:02
Megan E. Daly, MD, assistant professor of radiation oncology, UC Davis Cancer Center, discusses upcoming clinical trials involving radiation therapy for the treatment of lung cancer.
Просмотров: 135 OncLiveTV
Non-Small Cell Lung Cancer Clinical Trial
 
02:55
Nasser Hanna, MD, discusses a phase II trial of concurrent chemoradiation with consolidation Pembrolizumab for the treatment of inoperable or unresectable stage III non-small cell lung cancer (NSCLC). Hoosier Cancer Research Network: LUN14-179 http://www.hoosiercancer.org/clinical-trials
Просмотров: 226 Hoosier Cancer Research Network
Non-Small Cell Lung Cancer (NSCLC) Immunotherapy: Advancing Hope
 
07:39
SITC presents NSCLC Immunotherapy: Advancing Hope, the newest in a series of videos focusing on immunotherapy for NSCLC patients. This video provides an overview of the building blocks of the immune system and immunotherapy, while also highlighting some of the FDA approved immunotherapy treatments and potential side effects, and the importance of clinical trials. *This video was produced prior to the October 2016 FDA approvals of 1) TECENTRIQ® (atezolizumab, Genetech, Inc.) in patients whose disease progressed despite treatment with platinum-containing chemotherapy and 2) KEYTRUDA® (pembrolizumab; Merck & Co., Inc.) as first-line therapy in patients whose tumors express high levels of PD-L1 on an FDA-approved test, without certain genetic mutations (EGFR or ALK). As a leader in the field of cancer immunotherapy research and education, SITC will continue to update this video series as additional immunotherapy treatments become available. Access Companion Online Activity: https://www.cmeuniversity.com/course/disclaimer/113314
Просмотров: 10705 Society for Immunotherapy of Cancer
Clinical trials in lung cancer explained video
 
00:46
Can joining a clinical trial help you get better treatment for lung cancer? In this video from the National Comprehensive Cancer Network (NCCN), David Ettinger, MD, from the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, explains why treatment on a clinical trial might be best for some lung cancer patients. NCCN, a not-for-profit alliance of 21 leading cancer centers dedicated to improving the quality and effectiveness of care for cancer patients, provides free information, approved by top cancer doctors, at www.NCCN.com.
New Immunotherapy Drugs Offer Even More Treatment Options and Hope for Lung Cancer Patients
 
01:31
New clinical trials here at The James offer even more hope and options for lung cancer patients, thanks to new immunotherapy drugs recently approved for lung cancer treatments. These drugs work with the body’s own immune system, and they maintain lower toxicity, frequent tumor shrinkage and long-lasting responses for patients. And with new clinical trials researching their use in combination with other treatments, with surgery or, in some cases, even as the first treatment response for lung cancer, many patients are experiencing fewer side effects, shorter recovery times, and longer-lasting results.
What Cancer Patients Should Know: Latest Immunotherapy News from ASCO 2018
 
10:44
Our panel of immunotherapy experts discusses the latest cancer immunotherapy advances featured at the world’s largest oncology conference—the 2018 annual meeting of the American Society of Clinical Oncology (ASCO)—with topics including combination immunotherapy, biomarker development, CAR T cell therapies, and new approaches to immune-based cancer treatment. Panelists include Charles G. Drake, M.D., Ph.D., of NewYork-Presbyterian/Columbia University Medical Center, and Catherine Diefenbach, M.D., and Jeffrey S. Weber, M.D., of the Perlmutter Cancer Center at NYU Langone Health. Jill O'Donnell-Tormey, Ph.D., of the Cancer Research Institute, moderates. We present this video as part of the Answer to Cancer patient and caregiver education program of the Cancer Research Institute, and feature it as part of our sixth annual global awareness campaign, Cancer Immunotherapy Month, in June. This panel was recorded on June 4, 2018, in Chicago, IL.
Просмотров: 9309 Cancer Research Institute
How Do Cancer Clinical Trials Work and Should You Participate?
 
02:49
Many new cancer treatments, drugs and cancer research stem from clinical trials, which are research studies to determine the effectiveness of a particular cancer treatment. In this video, oncologist Dr. Stephen Lemon explains how #clinicaltrials work, including different trial phases, and how cancer patients may choose to volunteer for these studies, based upon their eligibility criteria. Visit http://www.oacancer.com/clinical-trials-for-cancer/ to learn more about clinical trials for cancer. #drstephenlemon #CancerResearch Dr Stephen Lemon is medical oncologist who now practices at Overlake Cancer Center Bellevue WA. He produces cancer information videos and web related cancer education projects. He invites you to follow his ongoing work at https://www.lightersideofcancer.com/
Просмотров: 2024 Oncology Associates
ValiSeek chief discusses upcoming clinical trials of lung cancer drug
 
04:26
Suzanne Dilly, the chief executive officer of ValiSeek, a division life sciences firm ValiRx (LON:VAL), explains the company’s deal with Clinical Accelerator to carry out the work on a Phase IIB study for lung cancer treatment VAL 401. The drug is being developed through a joint venture with Tangent Profiling to target patients with non-small-cell lung adenocarcinoma, the most common form of the disease.
Просмотров: 238 Proactive Investors Stocktube
Cancer Clinical Trials
 
02:34
Texas Oncology-Presbyterian Cancer Center Dallas patient Rebecca Hill discusses her fight against stage IV lung cancer. Her care team, led by Dr. Katherine Wang, enrolled her in a clinical trial with a drug that has since received FDA approval.
Просмотров: 345 TexasOncology
Cancer Clinical Trials
 
01:49
Sometime in the future, people may look back on today as the golden age in cancer research. "In the old days, we used cytotoxic drugs that kind of worked across the board, just sort of wiped out rapidly growing cells. The newer advances in molecular biology and biochemistry is that they're finding out what are the growth pathways that drive various cancers. And unfortunately it's complex; many cancers have several different pathways so when you block one, you may be able to reverse the cancer for a period of time and then it finds its way to get around it," says Dr. William Harwin, oncologist on Lee Memorial Health System's medical staff. As cancer treatment moves toward individual drug therapy, studies are honing in on these cancer pathways and trying to find ways to shut them down. That's where drug trials come into play. "That's what basically produces advances. And that is also a way in which we give the latest cutting edge therapies to patients," says Dr. Harwin. Clinical trials come in four phases. The first involves patients who have exhausted their options. It looks at the safety of a drug. The final phase generally comes after FDA approval. At any given time, people in Southwest Florida are taking part. Each drug has different qualifying characteristics that determine whether someone is eligible. It's the nature of trials that not everyone gets the experimental drug. "It's double-blinded, so there's absolutely no chance for bias or that someone could interfere with the results. So even though I had a patient on the trial, I don't know if they got the treatment drug or they got the placebo drug," says Dr. Harwin. Several drugs, including ones for lung, skin and breast cancer were tested locally, and went on to get FDA approval. "That's really exciting to know that I put a patient here in Fort Myers on a trial that lead to a new drug that's going to improve the treatment of breast cancer," says Dr. Harwin. As researchers attack cancer from the cellular level, it gives cancer doctors more options to fight it in the real world. View More Health Matters video segments at leememorial.org/healthmatters/ Lee Memorial Health System in Fort Myers, FL is the largest network of medical care facilities in Southwest Florida and is highly respected for its expertise, innovation and quality of care. For nearly a century, we've been providing our community with everything from primary care treatment to highly specialized care services and robotic assisted surgeries. Visit leememorial.org
Просмотров: 362 Lee Health
New clinical trials underway for advanced lung cancer patients
 
03:51
There was word this week of what is being described as a pioneering clinical trial being done in the U.K. for patients with advanced lung cancer. What's so novel about this development?Hari Sreenivasan spoke to Dr. Mark Kris, an oncologist at Memorial Sloan Kettering Cancer Center, about what makes this clinical trial so interesting.
Просмотров: 2237 PBS NewsHour
Governor Cuomo Announces Groundbreaking Clinical Trial of Cuban-Developed Lung Cancer Treatment
 
33:29
October 26, 2016, Buffalo - Governor Cuomo announced that the Buffalo-based Roswell Park Cancer Institute will launch a groundbreaking clinical trial of CIMAvax-EGF – a Cuban-developed lung cancer treatment.
Просмотров: 985 NYGovCuomo
Clinical Trials - Cancer
 
03:04
Bendigo Health discussions on clinical trials related to cancer treatment
Просмотров: 248 BendigoHealth PR
New Lung Cancer Study tests effectiveness of genomic therapy
 
01:51
Watch more and discuss: http://norwalk.itsrelevant.com/content/19695/whittingham-changing-lung-cancer-treatment A new drug through a clinical trial at Norwalk Hospital is changing the way doctors are treating lung cancer. "We've now been able to identity a couple of specific genetic changes that can be targeted with drugs. Right now it is standard of care to treat some patients who have a mutation in the gene called EGFR (epidermal growth factor receptor) with a drug called Tarceva or another drug calledafatinib,"said Dr. Richard Frank, medical oncologist and Director of Cancer Researcha at Norwalk Hospital. Lung cancer is the leading cause of cancer death in men and women.According to the American Cancer Society (ACS), each year more people die of lung cancer than of colon, breast, and prostate cancers combined. There are two major types of lung cancer, non-small cell and small cell. Diagnostic testing guides treatment by determining the type and stage of the cancer, as well as genetic mutations in the cancer cells. According to Dr. Richard Frank, the medicine targets a specific gene mutation in patients tumors. "This mutation is more common in people who did not smoke and developed lung cancer. There is a population especialy in young women, that is rising exponentially but we do not know why." With the new drugs, patients now have another treatment option other than traditional chemotherapy. "Now it's gene abnormality - pill. It is a targeted approach, said Dr. Frank. And Dr. Frank says the drugs are yielding promising results. "Not all the cells are killed but patients can enjoy remission of many months or many years in some cases. There has been a phase I trial already done and most of the patients responded so we know this pill is very active. We are now in the expansion trial meaning more people will recieve the drug, and probably as a result of this, the drug will recieve approval [from the FDA]. For more information about this clinical trial or about the cancer research program at Norwalk Hospital, please contact Jennifer M. Long, ANP-BC, nurse practitioner and clinical coordinator, Whittingham Cancer Center, 203-852-2996 or email Jennifer.long@norwalkhealth.org Produced By: Kwegyirba Croffie
Просмотров: 110 It's Relevant TV
MGH Clinical Trial for Lung Cancer: Targeted Therapies to Halt Tumor Growth
 
03:42
Linnea Duff tells her story about participating in a clinical trial of a potential new targeted treatment drug that has provided powerful evidence that it can halt or reverse the growth of lung tumors characterized by a specific genetic abnormality. In their report in the October 28 New England Journal of Medicine, a multi-institutional research team reports that daily doses of the investigational drug crizotinib shrank the tumors of more than half of a group patients whose tumors were driven by alterations in the anaplastic lymphoma kinase (ALK) gene. In another one-third of study participants, crizotinib treatment suppressed tumor growth. Fore more information visit: http://www.massgeneral.org/cancer/news/faq.aspx Press Release: http://www.massgeneral.org/about/pressrelease.aspx?id=1292
Просмотров: 1769 MassGeneralHospital
How does cancer immunotherapy work?
 
03:07
Traditionally, cancer treatment has revolved around chemotherapy, radiation and surgery. But thanks to groundbreaking immune checkpoint blockade research led by Jim Allison, Ph.D., winner of the 2018 Nobel Prize in Physiology or Medicine, we have a new way to treat cancer: immunotherapy. Rather than treating the cancer directly, immunotherapy trains the immune system to attack cancer. With immunotherapy, MD Anderson is able to effectively treat bladder cancer, head and neck cancers, Hodgkin’s lymphoma, kidney cancer, non-small cell lung cancer and melanoma. And through clinical trials, we’re expanding immunotherapy to treat more types of cancer and exploring more types of immunotherapy every day. Request an appointment at MD Anderson online at https://my.mdanderson.org/RequestAppointmentcmpid=youtube_appointment_immunotherapy or by calling 1-877-632-6789. Learn more about Jim Allison, Ph.D., who is chair of Immunolgy and executive director of the Immunotherapy platform of MD Anderson’s Moon Shots Program: https://www.mdanderson.org/newsroom/nobel-prize.html Learn more about immunotherapy: https://www.mdanderson.org/treatment-options/immunotherapy.html
Просмотров: 90329 MD Anderson Cancer Center
Patient to Patient: What You Need to Know About Cancer Immunotherapy
 
45:36
How does a cancer diagnosis interrupt your life? Why choose immunotherapy? Two patients offer two very different perspectives on life with cancer, choosing a clinical trial, and figuring out what's next in life. In this webinar designed for patients and caregivers, T.J. Sharpe and Donna Fernandez share their experiences with cancer immunotherapy as well as share advice for patients currently seeking or receiving immunotherapy treatment. T.J. Sharpe, was diagnosed with metastatic melanoma in 2012, just weeks after the birth of his second child. Not satisfied with the standard of care treatments offered to him, he and his family began exploring immunotherapy. Two clinical trials later, he is living a full life, now on maintenance Keytruda, devoting the bulk of his time to his family and to melanoma advocacy. T.J. writes a blog for philly.com called Patient 1. (The name of his blog was inspired by the first clinical trial he enrolled in at Moffit Cancer Center, in which he was the first patient ever to receive Yervoy and TIL (tumor-infiltrating lymphocytes, a type of adoptive cell transfer).) Donna Fernandez was first diagnosed with stage 4 lung cancer in 2012, when she went to the doctor believing she had a thyroid problem. At the time, Donna was working full time and doing dog agility several nights a week and every weekend. Her tumors did not respond to chemotherapy, and when faced with beginning a second chemotherapy regimen, Donna instead enrolled in an immunotherapy trial of nivolumab (Opdivo). Donna responded immediately. Her scans show that the tumors have remained stable. Donna continues training with her two dogs, Cotton and Barney. She says, “Opdivo has let me live my life exactly how I want to. People talk about a “new normal” after cancer, but I don’t have a new normal. I’m still living my old normal.” The "Cancer Immunotherapy and You" webinar series is produced by the Cancer Research Institute and is made possible with generous support from Bristol-Myers Squibb, with additional support from Regeneron, Sanofi Genzyme, and Adaptimmune. Browse our Cancer Immunotherapy and You Webinar Series playlist on YouTube or visit the Webinars page on our website to see other webinars in this series. http://www.cancerresearch.org/webinars
Просмотров: 16318 Cancer Research Institute
Lung cancer immuno-oncology clinical trial combinations: inhibiting IDO
 
01:32
There are numerous ongoing and planned clinical trials investigating immuno-oncology (IO) agents for lung cancer, particularly in combination with other classes of therapy moving forwards. Here, Alastair Greystoke, PhD, of the University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses the key combinations being investigated. Dr Greystoke highlights investigations combining checkpoint inhibitors with an inhibitor of IDO, which may be involved in IO resistance. He also covers the challenges being faced in developing these combination regimens, highlighting the struggle with prioritization and toxicity. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.
Просмотров: 42 VJOncology
Lung cancer clinical trial
 
01:04
This video is intended for non-US residents. A clinical trial is a research study involving people. Therapies to treat lung cancer today are the result of clinical trials from the past. For more information about clinical trials visit: www.nationallungcancerpartnership.org www.lungcancercoalition.org For more information on lung cancer and lung cancer treatments, visit: http://www.lifewithlungcancer.info
Просмотров: 366 LifeWithLungCancer
Clinical Trials - Lung Cancer Foundation of America (LCFA)
 
05:38
Leading lung cancer investigators Dr. Jessica Donington, Dr. David Johnson, Dr. Robert Figlin, Dr. David Carbone, Dr. Heather Wakalee and Dr. William Pao answer your questions, calm your fears and give hope regarding clinical trials and lung cancer treatments. Saving lives through funding lung cancer research is the purpose of Lung Cancer Foundation of America; a lung cancer organization founded by lung cancer advocates Kim Norris, Lori Monroe and David Sturges. LCFA will accomplish this goal by raising funds from the private sector and channeling those funds to lung cancer investigators, enabling clinicians and s to find effective ways to predict, detect and treat lung cancer. Lung Cancer Foundation of America strives to be a community resource for both the lung cancer patient and the lung cancer research communities. Learn more about Lung Cancer Foundation of America and donate to fund lung cancer research at www.lcfamerica.org.
Просмотров: 496 Lung Cancer Foundation of America
Immunotherapy Clinical Trials: Sue Scott’s Story of Survival
 
04:59
An inside look at a Center for Cancer Research trial with Dr. Christian Hinrichs and his patient, Sue Scott. Dr. Hinrichs conducts basic and clinical research to discover and develop novel T-cell therapies for the treatment of patients with cancer. This work includes a clinical trial of HPV-targeted tumor-infiltrating T cells for patients with HPV+ cancers, which has demonstrated that this treatment can mediate complete regression of cervical cancer in some patients. Dr. Hinrichs' laboratory also has discovered genes for T-cell receptors that target HPV, and his group is testing new gene therapy treatments based on these receptors for patients with advanced HPV+ tumors. The Center for Cancer Research (CCR) is a part of the National Cancer Institute. For more on CCR: https://ccr.cancer.gov/ To search for clinical trials: http://trials.cancer.gov
Просмотров: 2604 National Cancer Institute
Cancer survivor Philip Prichard’s clinical trial success story
 
01:23
Physicians at MD Anderson Cancer Center proposed a clinical trial for Philip Prichard using immunotherapy – a unique and personal approach to treating cancer tumors. After 8 weeks his tumor shrunk in half. After 13 months 75% of the tumor was gone. Learn more at http://makingcancerhistory.com
Просмотров: 1225741 MD Anderson Cancer Center
Dandelion Root Extract For Cancer Cure Treatment: Side Effects, Clinical Trials & Research
 
08:39
Dandelion Root Extract For Cancer Cure Treatment: Side Effects, Clinical Trial & Research Reports | Natural Healing Guides This is one of the best video you will ever come across online. This detail video is Based on Dandelion Root Extract cancer fighting capabilities, side effects, how to use it and cautionary measures to take. Frequently Asked Questions About Dandelion Root Cancer Cure Are Dandelion Root cancer Cure testimonials real. There are several testimonials on the use of Dandelion Root for cancer treatment but it is not covered in this video. Can dandelion root be used to cure breast and lung cancer. In the past, this highly effective herbal plant has been used to cure stomach, lung, breast and pancreatic cancer. Watch this video in full to learn more. Dandelion cancer research and clinical trials. What this video for Dandelion Root cancer research findings. Is dandelion root cancer cure procedure at no cost? The answer to this question is no. You will have to consult with your oncologist for more information on this. how to use dandelion extract for cancer. What this video for detail information on how Dandelion root Extract is used to cure cancer. Can Dandelion root extract be used for cancer cure and treatment? Yes this video has extensive information on this subject. WARNING: Please do not rely on this video alone when treating cancer, ensure you consult with your doctors or oncologist for safety and the proper procedure to follow.
Просмотров: 114 NaturalHealingGuides
Lung Cancer Clinical Trial: Chemotherapy with or without Opdivo
 
03:46
Learn about a clinical trial that may help answer questions about the role of immunotherapy in combination with chemotherapy in treating patients with advanced non-small cell lung cancer whose disease worsened after initial response to immunotherapy. http://hoosiercancer.org/clinical-trials/trial/lun15-233/
Просмотров: 28 Hoosier Cancer Research Network
Investigational cancer treatment study
 
01:58
A new investigational drug designed to stop cancer cells from reproducing may offer hope for patients with advanced solid tumor cancers. Clinical trials of TKM-PLK1 for qualified patients are now open at the Virginia G. Piper Cancer Center at Scottsdale Healthcare. TKM-PLK-1 targets a protein called polo-like kinase 1 (PLK1) that promotes tumor cell reproduction. It prevents the tumor from completing cell division, resulting in death of the cancer cell. The Virginia G. Piper Cancer Center at Scottsdale Healthcare will be among the first in the world to study the treatment in humans. The new drug is being developed as a treatment for patients with advanced solid tumor cancers who are not well served by current therapy. The Phase 1 clinical trial will evaluate the safety, tolerability and how the body metabolizes TKM-PLK1. Laboratory research showed the investigational compound may have effectiveness in treating colorectal, breast, non-small cell lung, and ovarian cancers. These diseases collectively affect more than 500,000 new patients each year in the United States. Individuals seeking information about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare may contact the cancer care coordinator at 480-323-1339, toll free at 1-877-273-3713 or via email at clinicaltrials@shc.org. For more information about Virginia G. Piper Cancer Center Clinial Trials, visit http://www.shc.org/clinicaltrials. Follow us on Twitter at http://www.twitter.com/SHCpublicinfo and on Facebook at http://www.facebook.com/scottsdalehealthcare.
Просмотров: 267 ScottsdaleHealthcare
What's New in Lung Cancer Research? | Dana-Farber Cancer Institute
 
25:20
The latest in lung cancer research, including information on clinical trials and targeted therapies. This presentation was originally given by Peter Hammerman, MD, PhD, a medical oncologist with Dana-Farber's Lowe Center for Thoracic Oncology, at the Living with Lung Cancer Forum held on Nov. 1, 2014 at Dana-Farber. For more information on lung cancer treatment and research, visit: http://www.dana-farber.org/Adult-Care/Treatment-and-Support/Treatment-Centers-and-Clinical-Services/Thoracic-Cancer-Treatment-Center.aspx
Просмотров: 450 Dana-Farber Cancer Institute
Zee News - Kusum stage IV lung cancer patient message to support clinical trails in India
 
01:51
It is short interview/ story of Kusum, a patient of stage IV lung cancer metastatic to brain (multiple tumors), to support and raise awareness of clinical trials in India, as taken by Zee news, a Hindi National News Channel in India. 5 yrs back, though being a non-smoker, at the age of 29, Kusum was diagnosed with stage IV. In 2014, when her disease got resistant to all available applicable medicines in India (though they were available in western countries via approval or clinical trials). She almost lost her life to this dreadful disease due to unavailability of any medicine. To get any cancer medicine approved in India, it should go for clinical trials, whether it is already approved in other countries or not. In India, there are only 1.4% of global trails going on, which leads to almost no access of the latest medicines/ treatment options for Indian citizens. Fortunately, after 3 months of battle of survival, Kusum came across a new clinical trial in India and decided to participate. After experiencing how clinical trial saved Kusum’s life and struggle associated to get access to latest medicines and clinical trial, Kusum and her husband Vivek have started to work actively with Patients, NGOs, Industry organizations, Regulators at FDA/ Govt and Doctors on clinical trial awareness and raising support to change the current clinical trial situation in India. So that no Indian patient should die due to unavailability of medicine that is available somewhere in world.
Просмотров: 18294 Vivek Tomar
Is the Next Big Step in Cancer Therapy: Personalized Vaccines?
 
03:59
An immunotherapy clinical trial at Moores Cancer Center at UC San Diego Health is testing a personalized vaccine using unique cancer mutations to boost an anti-tumor immune response. Tamara Strauss became the first patient to enroll in a first-of-its-kind study after spending more than three years living with stage IV pancreatic neuroendocrine cancer. Ezra Cohen, MD, associate director for translational science at Moores Cancer Center, and Stephen Schoenberger, PhD, professor of immunology at the La Jolla Institute for Allergy and Immunology, developed a new technology that identifies a patient’s unique targets that can be used to create a vaccine specific to each individual person. For more information about cancer treatment at Moores Cancer Center, visit: https://health.ucsd.edu/specialties/cancer/Pages/default.aspx For more information about the clinical trial visit clinicaltrials.ucsd.edu/trial/NCT03568058.
Просмотров: 1273 UC San Diego Health